T1	intervention 17 46	intraventricular chemotherapy
T2	eligibility 171 234	patients with leptomeningeal metastasis (LM) from breast cancer
T3	intervention-participants 312 314	17
T4	control 322 356	non-intrathecal (non-IT) treatment
T5	control-participants 360 362	18
T6	outcome 496 537	neurological improvement or stabilisation
T7	iv-bin-percent 541 544	59%
T8	cv-bin-percent 562 565	67%
T9	outcome 592 618	median time to progression
T10	iv-cont-median 622 630	23 weeks
T11	cv-cont-median 640 648	24 weeks
T12	outcome 659 674	Median survival
T13	iv-cont-median 694 704	18.3 weeks
T14	cv-cont-median 709 719	30.3 weeks
T15	outcome 823 849	Neurological complications
T16	iv-bin-percent 875 878	47%
T17	cv-bin-percent 887 889	6%
